1. Scrip
  2. >>Business

Poolbeg Startles Investors With Plan To Hook Up With Hookipa

 
• By Kevin Grogan

The new year is only a couple of days old but the Anglo-Irish biotech has agreed a sale to Hookipa that will create a US-listed entity around HB-700, which targets multiple KRAS mutations in lung, colorectal and pancreatic cancers, and Poolbeg's Phase II-ready drug which is designed to prevent cancer immunotherapy-induced cytokine release syndrome.

Merger concept

The news that Poolbeg Pharma is exploring a possible merger with Hookipa Pharma that would see the firm move its listing from London to the NASDAQ has excited their prospective boards but not gone down with shareholders.

Poolbeg, which has headquarters in the UK and Ireland, said it had entered into non-binding discussions for an all-share deal that would see it acquired by Hookipa which is based in Austria but is listed in New York. Poolbeg stockholders would receive 0

More from Deals

More from Therapy Areas